Betamethasone

Corticosteroid Glucocorticoid

Dosage & Administration Guidelines

Species Route Dose Frequency Duration & Clinical Notes
Dog PO 0.1-0.2 mg/kg q12-24h Duration: Varies; taper after initial response
Notes: Use lowest effective dose. For anti-inflammatory effects, lower doses may suffice; for immunosuppression, higher doses may be needed.
Dog IV/IM 0.1-0.5 mg/kg q24h Duration: As needed
Notes: For acute conditions, use injectable betamethasone sodium phosphate or acetate.
Cat PO 0.1-0.2 mg/kg q12-24h Duration: Varies; taper after initial response
Notes: Cats may be more sensitive to adverse effects; use caution.
Cat IV/IM 0.1-0.5 mg/kg q24h Duration: As needed
Notes: For acute conditions.
Horse IV/IM 0.02-0.05 mg/kg q24h Duration: As needed
Notes: For systemic anti-inflammatory effects. Intra-articular dose: 2.5-5 mg per joint, depending on joint size.
Cattle IV/IM 0.02-0.05 mg/kg q24h Duration: As needed
Notes: For ketosis, use as adjunct to glucose therapy. Observe withdrawal times.
Small Ruminants IV/IM 0.02-0.05 mg/kg q24h Duration: As needed
Notes: Use with caution; observe withdrawal times.
Rabbit PO/IM 0.1-0.2 mg/kg q12-24h Duration: Short-term; taper
Notes: Rabbits are sensitive to corticosteroids; use with caution.
Bird/Poultry IM 0.1-0.2 mg/kg q12-24h Duration: Short-term
Notes: Use with caution; may cause immunosuppression.

Clinical Indications & Species Uses

General Indications
  • Treatment of inflammatory and allergic conditions, immune-mediated diseases, and as an adjunct in shock therapy.
Dog (Canine)
  • Anti-inflammatory and immunosuppressive therapy for allergic dermatitis, atopy, autoimmune diseases (e.g., pemphigus, lupus), inflammatory bowel disease, asthma, and certain neoplasias (e.g., lymphoma).
  • Management of shock (as an adjunct) and cerebral edema.
Cat (Feline)
  • Anti-inflammatory and immunosuppressive therapy for allergic dermatitis, asthma, inflammatory bowel disease, and autoimmune diseases.
  • Management of shock (as an adjunct).
Horse (Equine)
  • Anti-inflammatory therapy for musculoskeletal conditions (e.g., arthritis, bursitis, myositis), allergic reactions, and respiratory diseases (e.g., recurrent airway obstruction).
  • Intra-articular injection for joint inflammation.
Cattle (Bovine)
  • Anti-inflammatory therapy for ketosis (as an adjunct to glucose therapy), allergic reactions, and musculoskeletal inflammation.
Small Ruminants (Sheep / Goat)
  • Anti-inflammatory therapy for allergic reactions, musculoskeletal inflammation, and respiratory diseases.
Rabbit & Small Mammals
  • Anti-inflammatory and immunosuppressive therapy for allergic conditions and inflammatory diseases.
Avian & Poultry
  • Anti-inflammatory therapy for allergic reactions and inflammatory conditions.
Exotic & Other Species
  • Anti-inflammatory therapy for inflammatory conditions in exotic species (e.g., reptiles, small mammals) as determined by a veterinarian.

Pharmacology & Mechanism of Action

Drug Class: Corticosteroid | Pharmacological Group: Glucocorticoid

Mechanism of Action: Betamethasone is a potent, long-acting synthetic glucocorticoid. It exerts its effects by binding to the glucocorticoid receptor in the cytoplasm, leading to translocation into the nucleus and modulation of gene transcription. This results in increased synthesis of lipocortin (which inhibits phospholipase A2, reducing arachidonic acid release and subsequent prostaglandin and leukotriene production), and inhibition of pro-inflammatory cytokines (e.g., IL-1, IL-6, TNF-alpha). It also suppresses immune cell function, including macrophage and T-cell activity, and stabilizes lysosomal membranes, thereby reducing inflammation and immune responses.

Pharmacodynamics: Betamethasone has potent anti-inflammatory, anti-allergic, and immunosuppressive effects. It is approximately 25-30 times more potent than hydrocortisone and has minimal mineralocorticoid activity. It reduces capillary permeability, inhibits leukocyte migration, and suppresses the release of inflammatory mediators. It also affects carbohydrate, protein, and fat metabolism, promoting gluconeogenesis, protein catabolism, and redistribution of body fat. Its duration of action is intermediate to long, depending on the formulation (e.g., acetate or phosphate esters).

⚑ Pharmacokinetics Summary

Absorption: Betamethasone is well absorbed after oral administration. After intramuscular or subcutaneous injection, absorption is slower and depends on the ester form: phosphate esters are rapidly absorbed, while acetate esters are slowly absorbed, providing a prolonged effect. Topical absorption is variable and depends on the site and skin condition.
Distribution: Betamethasone is widely distributed throughout the body. It crosses the placenta and is distributed into milk. It is bound to plasma proteins, primarily corticosteroid-binding globulin (CBG) and albumin, with a protein binding of about 64%.
Metabolism: Betamethasone is metabolized in the liver, primarily by reduction and conjugation (glucuronidation and sulfation). The metabolites are inactive.
Excretion: Metabolites are excreted primarily in the urine, with a small amount in feces. The elimination half-life is approximately 36-54 hours in dogs, but the biological half-life (duration of action) is longer (about 36-72 hours).
Half-Life: Dogs: 36-54 hours (plasma); Cats: approximately 2-4 hours (plasma); Horses: approximately 1-2 hours (plasma); Cattle: approximately 1-2 hours (plasma).
Bioavailability: Oral bioavailability is high (approximately 80-100%). Intramuscular bioavailability is also high, but the rate of absorption depends on the ester formulation.
Protein Binding: Approximately 64% in most species.

Available Formulations & Strengths

Oral Tablet 0.5 mg, 1 mg (PO)
Oral Solution 0.6 mg/mL (PO)
Injectable Solution (Sodium Phosphate) 4 mg/mL (IV/IM/SC)
Injectable Suspension (Acetate) 3 mg/mL (IM/Intra-articular)
Topical Cream/Ointment 0.05% - 0.1% (Topical)
Ophthalmic Suspension/Ointment 0.1% (Ophthalmic)

Contraindications & Clinical Warnings

Contraindications:
  • Systemic fungal infections
  • Known hypersensitivity to betamethasone or other corticosteroids
  • Use in animals with viral infections (especially without appropriate antiviral therapy)
  • Use in pregnant animals (especially during early gestation) unless the benefits outweigh risks
  • Use in animals with corneal ulcers (topical ophthalmic)
  • Use in animals with glaucoma (topical ophthalmic)
  • Concurrent use with live vaccines (immunosuppression may reduce vaccine efficacy)
Warnings & Clinical Precautions:
  • Use with caution in animals with diabetes mellitus, as corticosteroids may increase blood glucose.
  • Use with caution in animals with renal disease, cardiac disease, or hypertension.
  • Use with caution in animals with gastrointestinal ulcers or inflammatory bowel disease, as corticosteroids may exacerbate these conditions.
  • Prolonged use may cause iatrogenic hyperadrenocorticism (Cushing's syndrome).
  • Abrupt withdrawal after prolonged therapy may cause adrenal insufficiency; taper dose gradually.
  • Use with caution in young animals, as corticosteroids may retard growth.
  • In food animals, observe withdrawal times to prevent drug residues.
  • In horses, use with caution in animals with laminitis, as corticosteroids may increase risk.
  • Topical use on large areas or broken skin may cause systemic absorption.

Adverse Effects & Reactions

Common:

  • Increased thirst and urination (polyuria/polydipsia)
  • Increased appetite (polyphagia)
  • Panting (especially in dogs)
  • Weight gain
  • Lethargy

Serious / Severe:

  • Gastrointestinal ulceration and perforation
  • Pancreatitis
  • Iatrogenic hyperadrenocorticism (Cushing's syndrome)
  • Adrenal suppression
  • Diabetes mellitus or worsening of existing diabetes
  • Immunosuppression leading to increased susceptibility to infections
  • Ligament and tendon rupture (in horses)
  • Laminitis (in horses)

Rare:

  • Behavioral changes (agitation, aggression)
  • Hepatopathy
  • Thromboembolism
  • Osteoporosis with long-term use
  • Growth retardation in young animals

Key Drug Interactions

Interacting Drug / Class Clinical Effect & Mechanism Severity
Nonsteroidal anti-inflammatory drugs (NSAIDs) Increased risk of gastrointestinal ulceration and bleeding. High
Furosemide or other diuretics Increased risk of electrolyte imbalances (e.g., hypokalemia). Moderate
Insulin or oral hypoglycemic agents Corticosteroids may increase blood glucose, reducing the effectiveness of these agents; dose adjustment may be needed. Moderate
Phenobarbital or other hepatic enzyme inducers May increase the metabolism of betamethasone, reducing its efficacy. Moderate
Cyclosporine Additive immunosuppressive effects; may increase risk of infections. Moderate
Vaccines (live) Immunosuppression may reduce vaccine efficacy and increase risk of vaccine-induced disease. High

Overdose & Toxicity Management

Signs of Toxicity:

  • Polyuria and polydipsia
  • Polyphagia
  • Hyperglycemia
  • Gastrointestinal ulceration
  • Electrolyte imbalances (hypokalemia, hypernatremia)
  • Hypertension
  • Behavioral changes
  • Adrenal suppression (with chronic overdose)

Emergency Treatment Protocol: There is no specific antidote. Treatment is symptomatic and supportive. For acute overdose, induce vomiting if oral ingestion and within 2 hours (in dogs/cats), administer activated charcoal, and provide supportive care. Monitor blood glucose, electrolytes, and blood pressure. For chronic overdose, taper the drug gradually to allow adrenal recovery. In severe cases, treat with insulin for hyperglycemia, fluid therapy for electrolyte imbalances, and gastroprotectants (e.g., omeprazole, sucralfate) for GI ulceration.

Food Animal Withdrawal Times

πŸ₯© Meat: 7 daysπŸ₯› Milk: 3 days

Withdrawal times are estimates and may vary by country and formulation. Always follow label instructions and local regulations. For cattle, meat withdrawal is typically 7 days and milk 3 days. For other species, consult the label or a veterinarian.

Storage, Handling & Regulatory Information

Storage Temperature: Store at controlled room temperature (20-25Β°C, excursions permitted to 15-30Β°C).

Light Sensitivity: Light-sensitive β€” protect from direct exposure.

Handling & Special Conditions: Protect from light. Keep container tightly closed. Do not freeze injectable solutions. Store topical preparations away from excessive heat.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Betamethasone is approved for use in dogs and cats in certain formulations (e.g., oral tablets, injectable). It is also approved for use in horses. Not approved for food animals in the US.

Extra-Label (Off-Label) Use: In the US, extra-label use of betamethasone in food animals is prohibited or restricted under AMDUCA. It is not approved for use in food animals in some countries. In horses, use is regulated; check with racing authorities. In companion animals, extra-label use is permitted under a valid veterinarian-client-patient relationship.

Clinical Pearls & Practice Notes

πŸ’‘ Clinical Insights: Betamethasone is a potent corticosteroid used for its anti-inflammatory and immunosuppressive properties. It is important to use the lowest effective dose for the shortest duration possible to minimize adverse effects. Tapering the dose is essential after prolonged therapy to avoid adrenal crisis. In food animals, strict adherence to withdrawal times is critical. In horses, caution is advised due to the risk of laminitis. For intra-articular use, strict aseptic technique is required. Monitor animals for signs of infection, hyperglycemia, and GI ulceration. Avoid concurrent use with NSAIDs. Client education is important to ensure compliance and recognition of potential adverse effects.

References & Literature

  • πŸ“š Plumb's Veterinary Drug Handbook
  • πŸ“š Papich Veterinary Pharmacology and Therapeutics
  • πŸ“š Compendium of Veterinary Products (CVP)